DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Nimotuzumab is an investigational drug.
There have been 72 clinical trials for Nimotuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2016.
The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Squamous Cell, and Esophageal Neoplasms. The leading clinical trial sponsors are Biotech Pharmaceutical Co., Ltd., Peking University, and Sun Yat-sen University.
There are seventy-five US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Nimotuzumab
|A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma||Xin-Hua Xu||Phase 2|
|Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)||University of Saskatchewan||Phase 1/Phase 2|
|Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma||Sun Yat-sen University||Phase 2|
Top disease conditions for Nimotuzumab
Top clinical trial sponsors for Nimotuzumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Nimotuzumab||Start Trial||Binding molecules specific for HER3 and uses thereof||MEDIMMUNE, LLC (Gaithersburg, MD)||Start Trial|
|Nimotuzumab||Start Trial||Multispecific constructs||AbbVie Stemcentrx LLC (North Chicago, IL)||Start Trial|
|Nimotuzumab||Start Trial||Anti-EGFR activatable antibodies||CytomX Therapeutics, Inc. (South San Francisco, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|